ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET FORECAST 2023-2032

The Asia-Pacific amniotic membrane market growth analysis entails the evaluation of India, Australia & New Zealand, China, Vietnam, Thailand, South Korea, Japan, Indonesia, and Rest of Asia-Pacific. Japan has well-developed biotechnology sectors and is among the top leading countries. The country has collaborated with various companies across several regions. For instance, in 2018, Japan established the German Pavilion to provide the first common platform for German exhibitors under its ‘Made in Germany’ campaign and events. In addition, the country significantly invests in research and development by collaborating with healthcare capital firms. 

Similarly, Japan has collaborated with United States-based firms and is investing in the development of biotechnology. In 2018, Japan Investment Corporation (JIC) invested heavily in JIC-US initiatives for biotech and drug-discovery startups. Such developments in biotechnology are expected to expand amniotic membrane applications in Japan during the forecast period.

On the other hand, in Indonesia, amniotic membranes have witnessed significant growth in ophthalmology and cancer treatments. Some biologists and medical experts are clinically working on grafts and placenta formation. Moreover, several clinics in Indonesia opt for fresh amniotic membranes for grafts because of their widespread availability. The reliability of using fresh amniotic membranes as a biomaterial is studied due to availability, which boosts the Indonesia amniotic membrane market growth.

The Asia-Pacific amniotic membrane market assessment includes segmentation by product, application, and end-user. Market by product covers lyophilization amniotic membrane and cryopreserved amniotic membrane.

Amniotic membrane transplantation is widely used in dermatological and ophthalmological surgeries to promote wound healing and re-epithelialization. Cryopreserved amniotic membrane (CAM) is a therapy used for patients with ocular surface defects for a whole year. It decreases the need for repeat office visits and is often covered by insurance. In addition to dry eye, CAM may be used to treat chemical burns of the corneal epithelial and ocular surface defects such as those associated with epithelial basement membrane dystrophy, persistent epithelial defects, corneal ulcers, band keratopathy or bullous, recurrent corneal erosions, keratitis, etc.

Furthermore, CAM is widely used in ophthalmology because of its wound-healing, anti-inflammatory, and anti-angiogenic capabilities. Placement of these membranes is not associated with any unexpected long-term effects or significant adverse reactions.

Some of the leading companies operating in the global amniotic membrane market are Smith & Nephew PLC, MiMedx, etc.

Smith & Nephew is a multinational company dedicated to designing and manufacturing medical technology. The company specializes in orthopedics, trauma, advanced wound management, and sports medicine. The company operates globally in Africa, America, Asia-Pacific, Europe, and the Middle East. The company is headquartered in England, United Kingdom, and was founded in 1856.

GrafixPL from Smith & Nephew is developed as a wound cover for a wide variety of acute and chronic wounds in head-to-toe locations. It naturally conforms to complex human anatomies and is used in overexposed joint capsules, tendons, bones, and muscles.